Evotec AG has received a milestone payment of $2.8 million from Boehringer Ingelheim after a back-up compound in their strategic alliance advanced into a Phase I trial. The compound, which was discovered and optimized within the alliance, is being developed as a novel treatment for neuropathic pain. The alliance has involved working on multiple high priority targets across key therapeutic areas. So far it has resulted in 13 milestone payments from multiple programs. Dr Werner Lanthaler, chief...